TheraRadar
← Back
Data updated: Jun 28, 2026

X-GEN PHARMS INC

Generics

X-GEN PHARMS INC is a generic drug manufacturer focused on Oncology.

2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

X-GEN PHARMS INC's Key Drugs

X-GEN PHARMS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

X-GEN PHARMS INC's Recent FDA Approvals

New NDA/BLA approvals for X-GEN PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

X-GEN PHARMS INC's Therapeutic Areas

X-GEN PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
1 drugs

X-GEN PHARMS INC's Top Competitors

X-GEN PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

X-GEN PHARMS INC Pipeline Snapshot

Active clinical trials for X-GEN PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling